OMedLive

CME Presentations

Microsatellite-Instability High Gastrointestinal Tumors


Presentations


Speakers

  • Russell R. Broaddus, MD, PhD

    Russell R. Broaddus, MD, PhD

    Russell R. Broaddus, MD, PhD

    Professor, Department of Pathology

    Russell R. Broaddus, MD, is a professor with tenure in the Department of Pathology, Division of Pathology/Lab Medicine, at the University of Texas MD Anderson Cancer Center in Houston. He is one of two principal investigators for the NCI-funded Endometrial Cancer Sponsored Program of Research Excellence (SPORE) at MD Anderson. Currently, his research focuses on endometrial cancer, specifically, molecular mechanisms of pathogenesis, molecular diagnostics and clinical pathology laboratory assays for the identification of women with Lynch Syndrome. Dr. Broadus has authored more than 220 manuscripts in peer-reviewed journals, and is a two-time recipient of the John P. McGovern Outstanding Teacher Award from the MD Anderson Cancer Center/UT Health Graduate School of Biomedical Sciences.
  • Michael J. Overman, MD

    Michael J. Overman, MD

    Michael J. Overman, MD

    Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine

    Michael J. Overman, MD, is an associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. Dr Overman is focused on improving the outcomes for patients with pancreatic and intestinal cancers, with a strong interest in clinical trials and translational research. He is a principal investigator on numerous studies investigating immune-checkpoint therapy in gastrointestinal malignancies, and has been involved in various clinical trial studies involving small bowel adenocarcinomas. He has published articles in peer-reviewed journals that include the Journal of Clinical Oncology and Annals of Oncology. Dr Overman earned his MD from Johns Hopkins School of Medicine in Baltimore, Maryland.

CME Information

Microsatellite-Instability High Gastrointestinal Tumors: Guiding Immunotherapy with Genetics


LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Summarize the utility of available methods for determining dMMR or MSI status in patients with GI tumors
  • Apply dMMR or MSI test results to inform the selection and management of specific patients with MSI-H tumors
  • Evaluate the latest safety and efficacy data of checkpoint inhibitor therapies in patients with advanced MSI-H GI tumors
  • Integrate checkpoint inhibitors into clinical practice for the treatment of MSI-H GI tumors

Acknowledgement

This activity is supported by educational grants from Bristol-Myers Squibb and Merck Sharp & Dhome Corp., a subsidiary of Merck & Co., Inc.

Tuition

Complimentary

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements

Physician Continuing Education
Live Internet Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Releasae/Expiration

Live Activity
Tuesday, March 27, 2018 from 12:00pm – 1:00pm EST.

Enduring Material
The enduring material will be available from March 27, 2018 to September 27, 2018.

Target Audience

This activity is intended for Medical oncologists, GI internists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with GI cancers.

Estimated Time to Complete

This activity consists of one session which should take approximately 1 hour to complete.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.OMedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Disclosures

Presenters

Michael J. Overman, MD
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

Consulting Fees: Bristol-Myers Squibb, Roche
Contracted Research: Bristol-Myers Squibb, MedImmune, Merck, Roche

Russell R. Broaddus, MD, PhD
Professor, Department of Pathology The University of Texas MD Anderson Cancer Center

None

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Disclosures

Agnes Lee, PhD
Medical Director
PlatformQ Health Education, LLC

None

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unapproved/Off Label Use (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Discalimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com